The Shifting Landscape of Breast Cancer Imaging: Is CEM the Recent Alternative to MRI?
For years, Magnetic Resonance Imaging (MRI) has been the gold standard for preoperative breast cancer staging due to its high sensitivity. However, a new contender is challenging this status quo. Contrast-enhanced mammography (CEM) is emerging as a powerful tool that offers comparable performance in assessing tumor size and identifying malignant lesions.
By combining conventional mammography with contrast enhancement, CEM allows radiologists to better visualize tumor vascularity, providing critical data for surgical planning and the detection of multifocal or multicentric disease.
Precision in Practice: Comparing CEM and MRI Accuracy
When it comes to measuring the extent of a disease, the goal is to match the “ground truth” found in post-operative histopathology. Recent retrospective analysis involving 52 women with biopsy-confirmed breast cancer reveals a surprising level of agreement between CEM and MRI.
In terms of primary tumor detection, MRI identified all cases, while CEM detected 51 out of 52. While this small discrepancy is clinically significant in oncology, the measurements of tumor size were remarkably similar: an average of 24.9 mm on CEM compared to 25.2 mm on MRI.
The data shows a strong intraclass correlation coefficient of 0.975, indicating that both techniques are highly consistent with one another. However, the real advantage of CEM appeared when compared to histopathology.
- CEM Performance: Matched the histopathology mean measurement exactly at 32.6 mm.
- MRI Performance: Slightly overestimated the disease extent, with a mean measurement of 35.0 mm.
Navigating the Limitations of Imaging Modalities
Despite the promising results, neither tool is perfect. The analysis highlighted specific challenges where imaging interpretation becomes more complex, particularly in cases involving non-mass enhancement. In a small group of five patients, differences of more than 20 mm were observed.
Because accurate characterization of the disease burden informs every step of treatment planning, the ability to detect every single lesion remains paramount. The fact that MRI detected all lesions while CEM missed one suggests that MRI still holds a slight edge in complete lesion detection.
Future Trends: AI and the Evolution of Diagnostics
The future of breast cancer imaging is moving toward a more integrated, multi-modal approach. Beyond the comparison of CEM and MRI, there is a growing focus on the integration of AI-enhanced imaging into diagnostics. This evolution aims to further refine the concordance between imaging results and histopathology, potentially reducing the overestimation seen in some MRI cases or the under-detection in CEM.
As multiparametric MRI (mpMRI) and CEM continue to evolve, the medical community is moving toward “selected patient” protocols. This means choosing the imaging modality based on the specific needs of the patient, the availability of equipment, and the complexity of the suspected lesion.
Frequently Asked Questions
Yes, research shows CEM demonstrates comparable performance to MRI, with a high correlation coefficient (0.975) and an average tumor size measurement (24.9 mm) very close to that of MRI (25.2 mm).
In a recent study, CEM’s assessment of total disease extent matched the histopathology mean exactly (32.6 mm), while MRI slightly overestimated it (35.0 mm).
While CEM is a viable alternative in selected settings and is more available, MRI still demonstrates a slight advantage in detecting all lesions, which is critical for some clinical decisions.
Learn more about the latest in radiology: Explore detailed studies on preoperative disease extent and comparative staging techniques.
Join the Conversation
Do you believe AI will eventually eliminate the discrepancies between imaging and pathology? We want to hear from healthcare professionals and patients alike. Share your thoughts in the comments below or subscribe to our newsletter for more insights into medical imaging trends.
